Torrent Pharmaceuticals Limited

TORNTPHARM

INE685A01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:54 14/06/2024 BST			5-day change	1st Jan Change
2,883 ^INR	+0.33%		+1.40%	+25.06%

06-06	Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	MT
06-05	Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize Its Novel Gastrointestinal Drug in India	CI

Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024

May 24, 2024 at 02:01 pm

Torrent Pharmaceuticals Limited announced that at the board meeting held on 24 May, 2024 the Board of Directors acceded to the desire of Jinesh Shah to step down as the Director of the Company effective from 23 July 2024.

Latest news about Torrent Pharmaceuticals Limited

Torrent Pharma Signs Deal with Japan's Takeda to Market Acid-Related Disorders Drug in India	06-06	MT
Torrent Pharmaceuticals Enters into Non-Exclusive Patent Licensing Agreement with Takeda Pharmaceuticals to Commercialize Its Novel Gastrointestinal Drug in India	06-05	CI
Jefferies Adjusts Torrent Pharmaceuticals’ Price Target to INR3,070 From INR2,930, Keeps at Buy	05-27	MT
INDIA STOCKS-Indian shares at record highs, boosted by pharma stocks, Adani Ports	05-27	RE
Torrent Pharmaceuticals' Consolidated Profit Jumps in Fiscal Q4; EPS Tops Estimates	05-27	MT
Torrent Pharmaceuticals to Raise Up to INR50 Billion via Qualified Institutional Placement	05-27	MT
Torrent Pharma Board Approves to Raise INR 50,000 Million	05-25	CI
Torrent Pharmaceuticals Limited Announces Stepping Down of Jinesh Shah as the Director, Effective from 23 July 2024	05-24	CI
Torrent Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended 31 March, 2024, Payable on or Around 31 July, 2024	05-24	CI
Transcript : Torrent Pharmaceuticals Limited, Q4 2024 Earnings Call, May 24, 2024	05-24
Torrent Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-24	CI
Torrent Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-24	CI
Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports	05-14	RE
Torrent Pharmaceuticals Limited Receives Communication for Collection of Penalty from Deputy Commissioner of State Tax Ghaziabad, Uttar Pradesh	05-02	CI
Torrent Pharmaceuticals Limited Receives an Order from Deputy Commissioner of State Tax, Guwahati -A-99, Guwahati, Assam, Imposing a Penalty of INR 3,39,842	04-30	CI
Torrent Pharmaceuticals Limited Receives Order from Deputy Commissioner State Tax, Special Circle 1, Kunchanapalli, Andhra Pradesh	04-23	CI
Torrent Pharmaceuticals Limited Receives Order Passed by Deputy Commissioner of State Tax, Ropar Division, Punjab Imposing Penalty	04-19	CI
Torrent Pharmaceuticals Limited Receives an Order Passed Under Section 73 of the Goods and Service Act, 2017, Imposing A Penalty of INR 388,809.60	04-08	CI
Torrent Pharmaceuticals Limited Announces Change in Directorate , Effective 31 March 2024	04-01	CI
Torrent Pharmaceuticals Limited Announces Superannuation of Ashok Modi as Executive Director	02-29	CI
Nomura Adjusts Torrent Pharmaceuticals' Price Target to INR2,975 From INR2,156, Keeps at Buy	02-08	MT
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	02-05	MT
Jefferies Adjusts Torrent Pharmaceuticals' Price Target to INR2,930 From INR2,750, Keeps at Buy	02-05	MT
Torrent Pharmaceuticals Posts Gains in Fiscal Q3 Consolidated Net Profit	02-05	MT
Torrent Pharmaceuticals' Consolidated Profit in Fiscal Q3	02-02	MT

Chart Torrent Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Torrent Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The Company is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The Company's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The Company's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.

Sector

Pharmaceuticals

Calendar

20/06/2024 - Final dividend

Related indices

NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Torrent Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2,883 INR

Average target price

2,850 INR

Spread / Average Target

-1.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TORRENT PHARMACEUTICALS LIMITED	+25.06%	11.68B
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals